PsychedelicNewsBreaks Archive - Page 48 of 67

WednesdayMay 19, 2021 2:20 pm

PsychedelicNewsBreaks – Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Poised to Meet Demands of ‘Cannabis 2.0’

Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) is positioned in a market that is still relatively scant for certified extractors able to meet demand for concentrates from cannabis biomass. Having just achieved a milestone moment with commencement of production of 25,000 vape cartridges for the Canadian retail market, the company is set for opportunity amid “Cannabis 2.0,” a post-legalization era in Canada that has seen new consumption trends with accessibility of goods like drinks and vape products. “Demand for Pure Extracts’ Pure Pulls branded 510 Vape cartridges is strong in the provincial markets in Canada,” reads a recent…

TuesdayMay 18, 2021 1:15 pm

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Secures IRB Approval to Commence Study of Psilocybin Formulation in Treatment of Major Depressive Disorder

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, has announced that the Institutional Review Board ("IRB") at the University of the West Indies Hospital in Jamaica has granted approval to commence the study of its sublingual psilocybin formulation ("CYB001") in a Phase II clinical trial for patients suffering with major depressive disorder ("MDD"). Commencement of the trial is subject to final confirmation of study material specifications by Jamaica’s Ministry of Health. "IRB approval for our study protocols is an important step forward to begin testing our proprietary psilocybin formulation delivered via absorption under the tongue…

FridayMay 14, 2021 1:34 pm

PsychedelicNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Focuses ‘Covid-ID Lab’ Commercialization Strategy Initially on German Market

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience technology accelerator, recently entered a strategic distribution, storage and logistics agreement for its commercial 25-minute COVID-19 RT-PCR test system (“Covid-ID Lab”). In April, XPhyto announced its entry into the agreement with a full-fledged German pharmaceutical wholesaler and service provider. Under the agreement, the German partner will distribute, store and deliver Covid-ID Lab test kits to XPhyto’s customers in line with product specifications and relevant logistical and regulatory requirements in Germany. A recent article quotes XPhyto CEO and Director Hugh Rogers, who noted that the company had secured a strong partner…

FridayMay 14, 2021 9:56 am

PsychedelicNewsBreaks – WWC Conference Celebrates Women in Cannabis, Psychedelic Industries

The second-annual Womxn, Wellness and Cannabis Conference (“WWC Conference”) is expected to be the largest virtual event for women in the cannabis and psychedelic industries. Slated for May 26–27, the two-day event is hosted by Marigold PR in association with Lift & Co. Expo, a platinum partner and North America’s largest cannabis industry conference and tradeshow. The largest free event of its kind, the conference unites women globally for two days and features women-led panel discussions, Q&As and keynote speakers. The first day of the conference will focus on cannabis; the second day will focus on psychedelics. The conference agenda…

FridayMay 14, 2021 9:38 am

PsychedelicNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) CEO Shares Six Keys to Leadership Growth in “Forbes” Article

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) CEO Greg McKee was featured in a recent “Forbes” article touting six keys to leadership growth. In the article, McKee shared valuable insight into the most effective ways that leaders can grow and develop. The behaviors McKee encouraged include staying curious and stepping outside of your comfort zone as well as not waiting for experiences and making experiences as you go. McKee also urged potential leaders to never stop learning and, in fact, noted that they could learn from every experience. McKee also encouraged leaders to not be afraid of breaking with convention.…

ThursdayMay 13, 2021 11:53 am

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Collaborates to Potentially Develop New Therapy for Treatment-Resistant Psychiatric Disorders

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company advancing psychedelic therapeutics for various psychiatric and neurological conditions, recently acquired Adelia Therapeutics, thereby adding CYB003 to its pipeline. It subsequently made an equally important move when it inked a drug-development agreement with Catalent Inc. (NYSE: CTLT), a leading global provider of advanced delivery technologies, development and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. According to a recent article, “The agreement, which is scheduled to start this month, calls for the two companies to work together to potentially develop a novel, fast-acting therapy for treatment-resistant psychiatric…

WednesdayMay 12, 2021 11:47 am

PsychedelicNewsBreaks – Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Opens Functional Mushroom Direct-to-Consumer Store on Amazon

Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ), a plant-based extraction company focused on cannabis, hemp, functional mushrooms and the rapidly emerging psychedelic sector, has opened an online, direct-to-consumer, e-commerce store through its wholly owned subsidiary, Pure Mushrooms Corp. The store, which will sell Pure Mushrooms Reishi and Maitake product formulations, is on the Amazon platform. Pure Mushroom Reishi and Maitake formulations are available in convenient, gluten-free capsules; the company anticipates releasing a Lion’s Man formulation this summer. “We are excited to be on Amazon, the largest online marketplace and the most powerful platform in the world for brand…

TuesdayMay 11, 2021 9:44 am

PsychedelicNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) CEO Talks Business in Two Video Interviews

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) director and CEO Hugh Rogers was a featured guest on two different video interviews. In both interviews, Rogers shared key information and updates about XPhyto, a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities. During his InvestorIntel interview with host Peter Clausi, Rogers mentioned that the company had recently received European approval of its point-of-care SARS-CoV-2 (COVID-19) RT-PCR test system called Covid-ID Lab, which is now registered within the European Union as a commercial in vitro diagnostic (“CE-IVD”) test. During the interview, Rogers noted that the…

MondayMay 10, 2021 1:11 pm

PsychedelicNewsBreaks – Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Integrates Cutting-Edge Tech for Faster Throughput, Highest Quality

Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) has ordered a state-of-the-art Cosolvent Injection System (“CIS”) from British Columbia-based Vitalis. The investment will make Pure Extracts one of the first companies in the world to receive the system, which will position it for many benefits. The CIS will be an add-on that enhances Vitalis carbon dioxide extraction systems that Pure Extracts already uses in its facilities. “The CIS provides dramatically faster throughput capacities while maintaining the quality of the cannabis and hemp extracts,” reads a recent article. “Furthermore, the Vitalis CIS has been designed to achieve the optimal ethanol…

MondayMay 10, 2021 10:07 am

PsychedelicNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Enters Master Agreement with Leading CRO Clinlogix

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing clinical-stage compounds for diseases with unmet medical needs, has entered into a master service agreement with Clinlogix, a contract research organization (“CRO”). The agreement is a key step for initiating and supporting the clinical development of Tryp’s psilocybin-for-neuropsychiatric disorders, or PFN(TM) (“PFN”), program. Tryp noted that Clinlogix has global experience in providing CRO services for the development of novel pharmaceutical products, and the agreement outlines the collaboration between the two companies, as well as other clinical partners, will include medical writing, biostatistical analysis, data management and trial monitoring. The…

News and publishing service for psychedelic related companies

Contact us: 512.354.7000

PsychedelicNewsBreaks